Review article:: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients

被引：55

作者：

Mangel, AW ^{[1
]}

Northcutt, AR ^{[1
]}

机构：

[1] Glaxo Wellcome Inc, Gastroenterol Clin Res, Res Triangle Pk, NC 27709 USA

来源：

ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 1999年 / 13卷

关键词：

D O I：

10.1046/j.1365-2036.1999.00010.x

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Irritable bowel syndrome (IBS) is one of the most common gastrointestinal-related conditions. In this review, the safety and efficacy of alosetron, a potent and selective 5-HT3 receptor antagonist, in the treatment of IBS are discussed. Alosetron has been shown to produce statistically significant improvements in abdominal pain, stool consistency, stool frequency and urgency in female IBS patients. By contrast, no consistent improvement has been seen in male IBS patients treated with alosetron. The only adverse event of note with alosetron was constipation, and this represents a class effect of 5-HT3 receptor antagonists. In conclusion, alosetron is a safe and effective treatment for female IBS patients.

引用

页码：77 / 82

页数：6

共 14 条

[11] Central modulation of colorectal distension-induced blood pressure changes by alosetron, a 5HT3 receptor antagonist. [J].

Miura, M ;

Lawson, DC ;

Mangel, A ;

Clary, E ;

Pappas, TN .

GASTROENTEROLOGY, 1998, 114 (04) :A804-A805

[12] Alosetron, a 5HT3-receptor antagonist, is effective in the treatment of female irritable bowel syndrome patients. [J].

Northcutt, AR ;

Camilleri, M ;

Mayer, EA ;

Drossman, DA ;

Dukes, GE ;

Ehsanullah, RSB ;

Hamm, LR ;

Harding, JP ;

Heath, AT ;

Jacques, L ;

Wolfe, S ;

Kong, S ;

McSorley, D ;

Mangel, AW .

GASTROENTEROLOGY, 1998, 114 (04) :A812-A812

[13]

Scott CM, 1997, GASTROENTEROLOGY, V112, pA822

[14]

Thompson W. G., 1992, GASTROENTEROL INT, V5, P75

← 1 2 →